Sana Biotechnology (SANA) Share-based Compensation (2020 - 2026)

Sana Biotechnology has reported Share-based Compensation for 7 years, with the latest figure at $33.5 million in Q1 2026.

• Quarterly Share-based Compensation rose 377.74% year-over-year to $33.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $33.5 million (down 5.79% YoY) and the FY2025 annual result came in at $25.5 million, down 32.42% from the prior year.
• Share-based Compensation climbed to $33.5 million in Q1 2026 per SANA's latest filing, from $6.3 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $33.5 million in Q1 2026 and troughed at $3.4 million in Q1 2022.
• A 5-year average of $10.3 million and a median of $9.1 million in 2024 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2025 and 2026: Share-based Compensation tumbled 41.75% in 2025, then surged 377.74% in 2026.
• Over 5 years, Share-based Compensation stood at $10.6 million in 2022, then slipped by 25.12% to $7.9 million in 2023, then dropped by 18.85% to $6.4 million in 2024, then slipped by 1.54% to $6.3 million in 2025, then jumped by 429.38% to $33.5 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $33.5 million, $6.3 million, and $13.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.